Did you know there's a new player in town for managing atopic dermatitis (AD)?

     Tralokinumab is a medicine that works by targeting a key inflammatory pathway.

     Now, the big question was how well it works on different parts of the body.

     A group of 129 patients with moderate-to-severe AD were treated for 36 weeks.

     The study used the Eczema Area and Severity Index (EASI) to score the location and symptoms.

     So, what dropped the most?

     Surprisingly, the lower limbs saw the largest drop in scores, but every body part showed improvement

     Patients saw consistent improvements in their skin, with a big win for excoriation.

     Excoriation had the best improvement in severity and achievement rates.

     The outcome? Globally, EASI scores decreased. Why does this matter?

     It means the treatment was versatile, across different body parts and skin itch.

     Imagine being clear of win, body area and itch where AD shows.

    This treatment is a sure bet for fighting off AD. It does not matter body part or skin itch.

    The research took many different symptoms and body parts.  The good news is Tralokinumab dealt with them all.

    Tralokinumab works well on different areas of the body and varied symptoms of atopic dermatitis (AD).

Wake Up to Tralokinumab: Your Secret Weapon

Actions